

About Atmo Biosciences

Atmo Biosciences is developing an ingestible electronic pill-shaped sensor that profiles the gases within the gut. Developed by researchers at RMIT University, the Atmo Gas Capsule has the potential to revolutionise how gut disorders are diagnosed and managed.



Impact

Atmo Biosciences significantly matured their product and business strategy throughout their time in ANDHealth+, greatly reducing the risk for the business and for investors as they seek to raise capital. This included deciding on the initial therapeutic application of their Gas Capsule, identifying target partnering opportunities, and how to best execute them, as well as developing their clinical trial and regulatory strategy. Atmo also established an external clinical advisory board and had one of their key studies published in a prestigious Nature journal which triggered national and international media coverage across print, web and television.

Atmo Biosciences hired a CEO from industry and are now ready for investment, and with the work undertaken through ANDHealth+ are significantly de-risked for their potential investors. The next steps include securing funding to continue executing on the clinical trial and regulatory approval strategy.

Testimonial



“The ANDHealth+ process allowed us to look deeply at the areas that mattered for our business to ensure success. As an innovation based on academic discovery, the commercial guidance from the ANDHealth+ program was vital and provided us crucial access to advisors which we would not have been able to. Being able to reach out to some of Australia’s digital health leaders and get industry relevant advice, tailored to our specific challenges, has allowed us to navigate the commercialisation pathway from a clinically validated academic innovation towards market and investment readiness.”


Kyle Berean, Chief Technology Officer, Atmo Biosciences

Atmo Milestones

Milestones	Before ANDHealth+ 2017 Program	After ANDHealth+ 2017 Program
Selection of Therapeutic Indication	● ○ ○ ○ ○	● ● ● ○ ○
Business Strategy	● ● ○ ○ ○	● ● ● ○ ○
Clinical Development Strategy	● ● ○ ○ ○	● ● ● ● ○
Legal Strategy	● ○ ○ ○ ○	● ● ● ○ ○
Investment Readiness	● ○ ○ ○ ○	● ● ● ● ○
Brand Awareness	● ○ ○ ○ ○	● ● ● ○ ○

*Note: Content in this case study has been approved by Atmo Biosciences

Challenges and Delivery



Atmo Biosciences and ANDHealth

Atmo Biosciences was selected from over 50 companies to be part the ANDHealth+ 2017 program. The ANDHealth+ program assists Australian mid-stage digital health companies to meet key investor, partner and customer requirements around clinical and commercial validation. ANDHealth+ requires no equity consideration, provides the company with a bespoke advisory panel, ANDHealth, contributes A\$60,000 to securing relevant third-party expertise and cohort companies also benefit from over \$150,000 worth of in-kind offerings, including technical platform services, media & communications, insurance, human resources, intellectual property and legal support.